High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered☆,☆☆,★,★★
References (53)
- et al.
Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids
Metabolism
(1984) - et al.
Comparative androgenicity of oral androgens, determined by steroid-induced decrements in high density (alpha) lipoproteins: Studies utilizing testosterone, methyltestosterone, 19-nortestosterone, 17-methyl nortestosterone and 17-ethyl nortestosterone
Am J Med
(1957) - et al.
Sex hormones and high density lipoproteins in healthy males
Atherosclerosis
(1979) - et al.
Plasma testosterone, high density lipoprotein cholesterol and other lipoprotein fractions
Am J Cardiol
(1981) - et al.
The influence of androgens, estrogens and related steroids on serum lipids and lipoproteins: Observations in hypogonadal and normal human subjects
Am J Med
(1958) - et al.
Relationship of plasma HDL-cholesterol to testosterone, estradiol, and sex-hormone-binding globulin levels in men and women
Metabolism
(1983) - et al.
A comparative study of the metabolic fate of testosterone, 17a-methyl-testosterone, 19-nortestosterone, 17a-methyl-19-nor-testosterone and 17a-methyl-estr-5(10)-ene-17b-ol-3-one in normal males
Clin Chim Acta
(1961) - et al.
Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy
Metabolism
(1983) - et al.
Short-term effects of testolactone on human testicular steroid production and on the response to human chorionic gonadotropin
Fertil Steril
(1985) - et al.
Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis
Metabolism
(1982)
Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II
J Biol Chem
Serum transaminase (GOT,GPT) and lactic dehydrogenase activity during treatment with methyl testosterone
Clin Chim Acta
Relationship of lipoproteins and apolipoproteins to sex hormones and binding capacity of sex hormone binding globulin (SHBG) in healthy Finnish men
Metabolism
Serum high density lipoprotein subclasses, testosterone and sex-hormone-binding globulin in Trinidadian men of African and Indian descent
Atherosclerosis
Fat distribution, endocrine and metabolic profile in obese women with and without hirsutism
Metabolism
Response of serum testosterone and its precursor steroids, SHBG and CBG to anabolic steroid and testosterone self-administration in man
J Steroid Biochem
High density lipoproteins as a protective factor against coronary heart disease
Reduced high-density lipoprotein-cholesterol in power athletes: Use of male sex hormone derivates, an atherogenic factor
Int J Sports Med
High-density lipoprotein cholesterol in bodybuilders ν powerlifters: Negative effects of androgen use
JAMA
Anabolic steroid use among athletes: Changes in HDL-C levels
Phys Sports Med
HDL-C in five elite athletes using anabolic-androgenic steroids
Phys Sports Med
Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity
Med Sci Sports Exer
Altered serum lipoprotein profiles in male and female power lifters ingesting anabolic steroids
Phys Sports Med
Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders
Int J Sports Med
Relationship of high density lipoprotein cholesterol with total and free testosterone and sex hormone binding globulin
Acta Endocrinol
Alphalipoproteinemic effects of androgenic-anabolic steroids in athletes
Ann Sports Med
Cited by (134)
Testosterone Replacement Therapy in Hypogonadal Men
2022, Endocrinology and Metabolism Clinics of North AmericaCitation Excerpt :Nasal testosterone must be applied three times a day to maintain serum testosterone within the adult male range. As discussed above, the currently available 17 alpha-alkylated modified testosterone tablets should not be used for testosterone replacement because of possible liver toxicity29,30 and more marked effects on lowering HDL cholesterol and increasing LDL cholesterol concentrations.26 Testosterone undecanoate has been available as 40 mg capsules (Andriol Testocaps) for many decades outside of the United States.60,61
Continuing the search for a hormonal male contraceptive
2020, Best Practice and Research: Clinical Obstetrics and GynaecologyCitation Excerpt :Oral androgens may lead to more changes in the lipoproteins that may affect HDL or LDL-cholesterol concentrations because of the first pass effect in the liver of about 20% [55,56]. Further studies are required to determine what effects nonaromatizable androgens will have on changes in HDL- and LDL cholesterol [57], and the impact of different classes of progestins on lipid levels. For hormonal combinations that incorporate more androgenic progestins, such as oral levonorgestrel, dose-dependent decreases in HDL cholesterol and weight gain have been observed, without significant changes in LDL-cholesterol levels [58].
Testosterone and the aging male: To treat or not to treat?
2010, MaturitasAtherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice
2006, Journal of Lipid ResearchCitation Excerpt :In conclusion, our results show that testosterone deficiency enhances atherosclerosis in male mice, indicating a protective role of androgens in sex-matched individuals. These observations are supported by data from human (13, 14, 19, 20) and mouse (21, 22) studies. Mechanisms involved in the loss of atheroprotection in castrated mice are related to increases in plasma levels of apoB-LPs and anti-OxLDL autoantibodies and the decreased affinity of LDL for its receptors.
Sexuality and reproduction, an important field in endocrinology
2006, Endocrinologia y NutricionAnabolic androgenic steroids and cardiomyopathy: an update
2023, Frontiers in Cardiovascular Medicine
- ☆
Supported in part by Grant No. AM17047 from the Diabetes Endocrinology Research Center.
- ☆☆
The views, opinions, and findings in this report are those of the authors and should not be construed as an official Department of the Army position, policy, or decision.
- ★
Presented at the Western Meeting, American Federation for Clinical Research, Carmel, CA, February 16–19, 1988 (Clin Res 36:122A).
- ★★
This is a US government work. There are no restrictions on its use.